Biopharma | May 20, 2026
IGI’s new drug candidate ISB 2301 to target solid tumors
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
The next-generation proteomics platform powered by Olink™ Explore HT enables simultaneous analysis of thousands of proteins from a single sample
Collaboration with Siddhi Diagnostics combines genomics and advanced imaging capabilities to strengthen precision diagnostics in high-growth suburban markets
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
Discussions during the meeting focused on strengthening India’s preparedness against zoonotic diseases and climate-sensitive health challenges
Union health ministry secretary Punya Salila Srivastava lauds HLL’s six decades of contribution to public healthcare and social development
Deployment aims to improve serialization efficiency by 45% and enhance regulatory compliance across global export markets
The country’s strength lies not just in technology availability but in adoption behaviour
The company reported free cash flow of Rs. 2,590 Mn for FY26
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
Subscribe To Our Newsletter & Stay Updated
